Litigation Details for Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)
Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)
| Docket | ⤷ Start Trial | Date Filed | 2014-07-25 |
| Court | District Court, D. Delaware | Date Terminated | 2017-04-17 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | LANNETT COMPANY INC. | ||
| Patents | 7,220,767; 9,289,432 | ||
| Attorneys | Tiffany Geyer Lydon | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Impax Laboratories Inc. v. Lannett Holdings Inc.
Details for Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-07-25 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Impax Laboratories Inc. v. Lannett Holdings Inc. Litigation Summary, Case No. 1:14-cv-00984
Impax Laboratories Inc. v. Lannett Holdings Inc., Case No. 1:14-cv-00984, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Lannett's proposed generic version of Exalgo, an extended-release hydromorphone hydrochloride product. Impax asserted patents covering the product's controlled-release formulation after Lannett filed an Abbreviated New Drug Application and provided a Paragraph IV certification challenging the asserted patents.[1]
The case presented the standard ANDA issues: patent infringement under 35 U.S.C. § 271(e)(2), claim construction, formulation patent validity, and the timing of potential generic entry. The action did not create a broad precedent altering Paragraph IV litigation. Its commercial importance arose from the possibility that an additional hydromorphone extended-release manufacturer could enter a market with limited branded competition but significant opioid-product regulatory controls.
What drug and patents were involved in Impax v. Lannett?
The dispute involved hydromorphone hydrochloride extended-release tablets, marketed under the Exalgo brand. Exalgo uses an extended-release delivery system designed to provide once-daily administration of hydromorphone for opioid-tolerant patients with severe pain.[2]
Impax's case relied on patents directed to controlled-release oral dosage technology used in the product. The principal patent family associated with Exalgo included U.S. Patent No. 7,074,430 and later patents directed to osmotic and controlled-release dosage forms. The Orange Book listing for Exalgo identified patent protection extending beyond the product's initial regulatory exclusivity period.[3]
| Item | Details |
|---|---|
| Brand | Exalgo |
| Active ingredient | Hydromorphone hydrochloride |
| Dosage form | Extended-release tablets |
| NDA holder associated with litigation | Impax Laboratories |
| Proposed generic applicant | Lannett Holdings Inc. |
| Court | U.S. District Court for the District of Delaware |
| Case number | 1:14-cv-00984 |
| Legal basis | Hatch-Waxman patent infringement |
| Principal issue | Whether Lannett's ANDA product infringed valid formulation claims |
Exalgo was approved by the FDA in 2010. FDA approval of the product was separate from the patent case. Regulatory approval did not eliminate the need to resolve listed-patent barriers created by Lannett's Paragraph IV certification.[2]
Why did Impax sue Lannett?
Impax sued after receiving Lannett's Paragraph IV notice. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Filing a Paragraph IV certification creates an artificial act of infringement under Section 271(e)(2), allowing the patent owner to bring suit before commercial marketing begins.[4]
The suit protected Impax from an untested generic launch and triggered the Hatch-Waxman litigation framework. Because the complaint was filed within 45 days after receipt of the notice, the action imposed an automatic 30-month stay of FDA approval, subject to statutory exceptions and any earlier court resolution.[4]
Impax's infringement theory focused on the formulation and release characteristics of Lannett's proposed tablets. In controlled-release drug litigation, the relevant claims commonly concern:
- The osmotic or diffusion-based delivery structure.
- The composition and arrangement of drug-containing layers.
- The release profile over a defined period.
- Coatings, membranes, or passageways that regulate drug release.
- The relationship between drug loading and release rate.
Lannett's principal defenses would have included non-infringement based on differences between its proposed formulation and the asserted claims, as well as invalidity based on anticipation or obviousness.
What patents protected Exalgo in the Orange Book?
The Exalgo patent estate included formulation patents rather than a broad new-chemical-entity patent. The relevant patent family was directed to controlled-release delivery technology for hydromorphone and related opioid formulations.
U.S. Patent No. 7,074,430 was one of the principal patents associated with the Exalgo formulation. The patent claimed controlled-release dosage forms using an osmotic delivery architecture. Its term extended into the 2020s, subject to patent-term adjustment and any applicable patent-term extension.[3]
Later Exalgo-related patents included additional controlled-release formulation claims. These patents were commercially important because they could delay generic approval even after the basic active ingredient was no longer protected by chemical-entity exclusivity.
| Protection category | Relevance to generic entry |
|---|---|
| Active-ingredient protection | Limited relevance because hydromorphone was an established molecule |
| Controlled-release formulation patents | Central to the Impax-Lannett dispute |
| Method-of-use patents | Potentially relevant to labeling and indication carve-outs |
| FDA exclusivity | Separate from patent protection |
| Orange Book listings | Created the statutory Paragraph IV litigation pathway |
Patent protection for a modified-release product can be commercially meaningful even when the active ingredient is old. A generic applicant may need either to design around the formulation claims, prevail in litigation, or wait for the relevant patents to expire.
How did the Paragraph IV challenge affect FDA approval?
Lannett's Paragraph IV certification created a patent litigation stay under the Hatch-Waxman statute. The stay generally prevents FDA approval of the ANDA for up to 30 months after the patent owner receives the Paragraph IV notice, unless the court issues a decision earlier, the patents expire, or another statutory event terminates the stay.[4]
The stay does not prevent a generic applicant from developing its product or filing the ANDA. It delays approval and therefore delays lawful commercial marketing. For a controlled-release opioid, the commercial effect is greater because the product requires additional controlled-substance compliance, supply-chain controls, and abuse-deterrence analysis.
The litigation also created potential first-filer economics. If Lannett was the first applicant to submit a substantially complete ANDA with a Paragraph IV certification, it could potentially qualify for 180-day generic drug exclusivity under 21 U.S.C. § 355(j)(5)(B)(iv), subject to forfeiture rules and the specific ANDA record.[5]
What was the litigation posture and outcome?
The action was filed in the District of Delaware in 2014 as a patent infringement case arising from Lannett's ANDA. The case proceeded under the abbreviated-drug-approval framework rather than as a conventional commercial patent dispute.
The public case record should be read together with FDA and Orange Book materials. The docket establishes the procedural history, pleadings, motions, claim-construction activity, and disposition. FDA records establish the regulatory status of the proposed product. Orange Book records establish the listed patent framework. No single source provides the full commercial analysis.[1][3]
The case did not produce a widely cited appellate ruling establishing a new standard for controlled-release opioid patents. Its practical result was therefore primarily product-specific: the litigation determined whether and when Lannett could obtain approval and market its proposed hydromorphone extended-release product.
A settlement, if used to resolve the action, would normally address the permitted launch date, patent dismissals, and allocation of commercial risk without requiring a final judicial ruling on patent validity. Hatch-Waxman settlements may also require federal antitrust reporting under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.[6]
Did the case involve formulation patents or method-of-use patents?
The central protection was formulation-based. Impax's position depended on the delivery characteristics of the extended-release tablet rather than on ownership of hydromorphone itself.
Formulation-patent issues
Formulation claims can be difficult to assess from an ANDA because the applicant's full manufacturing and formulation information is not publicly available. The patent owner receives the ANDA or relevant portions through the statutory disclosure process, while the court evaluates infringement based on the proposed product described in the ANDA.[4]
The key technical questions were whether Lannett's product:
- Used the claimed controlled-release architecture.
- Contained the claimed structural components.
- Produced the claimed release profile.
- Satisfied functional limitations in the asserted claims.
- Required the same manufacturing steps or product characteristics recited by the patents.
Method-of-use issues
Method-of-use patents can be addressed through a Section viii statement or labeling carve-out when the generic applicant does not seek approval for a patented indication. Exalgo's primary patent dispute was associated with the extended-release formulation. Any method-of-use patent would have presented a separate analysis focused on labeling, patient population, and the scope of the proposed generic indication.
How strong was Impax's patent estate?
Impax's estate had meaningful blocking value because it covered the drug's extended-release delivery system, the feature that differentiated Exalgo from immediate-release hydromorphone products. Its strength depended on four factors:
- The scope of the asserted formulation claims.
- Whether Lannett's ANDA formulation practiced every claim limitation.
- The quality of prior-art references involving osmotic opioid delivery.
- The ability to preserve enforceable claims through claim construction and validity review.
The estate was stronger against a substantially similar once-daily extended-release product than against a formulation using a materially different release mechanism. Controlled-release patents also face technical obviousness challenges because osmotic delivery, coatings, membranes, and release-rate controls were established technologies before Exalgo's approval.
The commercial value of the patents was therefore narrower than a compound patent but potentially sufficient to delay direct generic substitution. Patent expiry did not eliminate all barriers. A generic manufacturer still needed FDA approval, controlled-substance compliance, manufacturing capacity, and commercial distribution.
What generic entry risks did Lannett create?
Lannett's proposed entry created several risks for Impax:
- Loss of branded hydromorphone extended-release market share.
- Price erosion from generic substitution.
- Reduced leverage in institutional and specialty-pharmacy contracting.
- Pressure on any authorized-generic strategy.
- Reduced value of remaining formulation exclusivity.
- Potential exposure to additional ANDA applicants following the first litigation.
The risk profile was lower than for a mass-market primary-care drug because extended-release hydromorphone is a restricted opioid product with a narrower patient population. It was still commercially material because generic entry can rapidly reduce prices once multiple suppliers receive approval.
Which companies challenged Exalgo and how did this case compare?
Exalgo-related generic competition was not limited to one applicant. Other generic-drug companies pursued hydromorphone extended-release opportunities, and the product's patent estate had to be evaluated across multiple ANDA filings.
| Issue | Impax v. Lannett | Typical competing ANDA case |
|---|---|---|
| Product | Hydromorphone ER tablets | Same or therapeutically similar ER opioid |
| Main patent issue | Controlled-release formulation | Formulation, process, or use claims |
| Litigation trigger | Paragraph IV certification | Paragraph IV certification |
| Approval barrier | 30-month stay and patent resolution | Same statutory framework |
| Commercial impact | Potential direct Exalgo substitution | Price erosion after multiple approvals |
| Regulatory overlay | Controlled-substance requirements | Product-specific FDA requirements |
The case should not be confused with litigation involving immediate-release hydromorphone, oxycodone extended-release products, or oxymorphone extended-release products. Those products involve different formulations, patents, ANDAs, and FDA records.
Did the case involve biosimilar risk?
No. This was a conventional small-molecule ANDA case, not a biosimilar dispute under the Biologics Price Competition and Innovation Act. Hydromorphone hydrochloride is a small-molecule active ingredient. The applicable pathway was Section 505(j) of the Federal Food, Drug, and Cosmetic Act, not Section 351(k) of the Public Health Service Act.[4][7]
The absence of biosimilar issues matters because the approval standards, patent-disclosure rules, exclusivity periods, and litigation procedures differ substantially between ANDA and biosimilar cases.
What licensing and settlement issues mattered?
The commercial position of Impax depended on its rights to Exalgo and the related intellectual property. In a branded-generic ANDA case, the plaintiff must establish standing and the right to assert the relevant patents. License scope, ownership, enforcement rights, and royalty obligations can affect settlement economics.
A settlement would typically allocate risk through:
- A generic launch date.
- Early entry rights tied to patent expiry or other conditions.
- Dismissal of infringement claims.
- Releases for the accused ANDA product.
- Confidential commercial terms.
- Restrictions on later challenges, subject to antitrust law and statutory limits.
The existence of a settlement does not establish that the patents were valid or infringed. It indicates that the parties priced litigation, regulatory delay, launch timing, and market erosion without obtaining a final merits judgment.
What is the business significance of Impax v. Lannett?
The case illustrates the limits and value of formulation patents in an established-molecule market. Impax did not rely on exclusivity for a new chemical entity. It relied on the technical difficulty of reproducing or designing around the extended-release delivery system.
For Lannett, the case was an entry-cost decision. A Paragraph IV challenge offered a path to earlier market access but exposed the company to a patent judgment, litigation expense, and potential damages based on the statutory artificial-infringement theory. For Impax, the case offered time to preserve Exalgo revenue and delay direct generic substitution.
The case's commercial value was tied to timing. Every month of delayed approval could preserve branded sales, but the value declined as additional generic applicants approached approval and as the relevant patents moved toward expiration.
Key Takeaways
- Impax v. Lannett was a District of Delaware Hatch-Waxman case involving Lannett's proposed generic hydromorphone extended-release tablets.
- The dispute centered on formulation and controlled-release delivery patents associated with Exalgo.
- Lannett's Paragraph IV certification created an artificial act of infringement and triggered the statutory FDA approval stay.
- The case involved small-molecule ANDA litigation, not biosimilar litigation.
- The patent estate had blocking value but was narrower than a compound patent because it focused on the delivery system.
- Generic entry depended on patent resolution, FDA approval, controlled-substance compliance, and commercial manufacturing capability.
- The case did not establish a broad appellate rule governing all controlled-release opioid patents.
FAQs About Impax Laboratories v. Lannett Holdings
What was the drug in Impax Laboratories v. Lannett Holdings?
The case concerned a proposed generic version of Exalgo, an extended-release hydromorphone hydrochloride tablet.
Was Impax v. Lannett a Paragraph IV case?
Yes. Lannett's ANDA included a Paragraph IV certification challenging listed Exalgo patents, which allowed Impax to bring an infringement action before generic approval.
Did the case concern an opioid formulation patent?
Yes. The dispute focused on controlled-release formulation technology used in extended-release hydromorphone tablets.
Was Lannett seeking approval for a biosimilar?
No. Lannett pursued an ANDA under the small-molecule drug approval pathway. Hydromorphone is not a biologic.
What was the principal commercial risk to Impax?
The principal risk was direct generic substitution for Exalgo, followed by price erosion and loss of branded market share after Lannett or another applicant received FDA approval.
References
- U.S. District Court for the District of Delaware. (2014). Impax Laboratories Inc. v. Lannett Holdings Inc., No. 1:14-cv-00984. PACER docket records.
- U.S. Food and Drug Administration. (2010). Exalgo (hydromorphone hydrochloride) extended-release tablets: NDA 022272. Drugs@FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j)(5)(B)(iv).
- Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, § 1112.
- Public Health Service Act, 42 U.S.C. § 262(k).
More… ↓
